Latest Podcasts

Candida Infections Board Review

By Olga Klinkova, MD

June 12th, 2026

Dr. Olga Klinkova, Infectious Diseases clinician at Moffitt Cancer Center and Research Institute, conducts a board review session on Candida Infections targeted towards the medical resident or Infectious Diseases Fellow. Topics discussed include a comparison and contrast of the different Candida species, information on Candida auris, Candidemia, and disseminated (hepatosplenic) candidiasis. Also discussed are novel antifungals used for azole-resistant candidiasis. Guidelines based reference sources are also mentioned.

Antimicrobial Side Effects: The Zebras, Not the Horses

By Yanina Pasikhova, Pharm.D.

June 8th, 2026

Dr. Yanina Pasikhova, Infectious Diseases Pharmacist at Moffitt Cancer Center and Research Institute, presents a talk on three lesser well known adverse drug effects involving antimicrobials. Dr. Pasikhova discusses the link between voriconazole and bone pain, the association between posaconazole and refractory hypertension and hypokalemia, and the neurological effects of of metronidazole therapy. Clinical pearls are provided for each interaction discussed.

Rickettsial Infections

By Leigh Ann Medaris, MD

May 22nd, 2026

Dr. Medaris, Chief of Infectious Diseases at Bay Pines Medical Center in St. Petersburg, Florida, conducts a review of Rickettsial Infections. After starting with an overview of the genus Rickettsia, Dr. Medaris moves on to discuss Rocky Mountain Spotted Fever, R. Parkeri, Mediterranean Spotted Fever, and Rickettsial Pox. African Tick Bite Fever is next discussed, followed by Sylvatic and Murine Typhus. Lastly, Dr. Medaris discusses Coxiella infections. Though not strictly a Rickettsiosis, it shares similarities with the Rickettsial group. The lecture is suitable for board review or for gaining further knowledge regarding these unusual pathogens.

PrEPare for a PEP Talk

By Drew Wilson, Pharm.D

May 4th, 2026

Dr. Drew Wilson, ID Pharmacy Resident, discusses the new options for pre-exposure prophylaxis (PrEP) to prevent HIV infection. Options discussed include oral PrEP (Truvada, Descovy), cabotegravir, and a newer option, lenacapravir. A prescribing algorithm is also presented, and the topic of developing resistance is also covered. Lastly, Dr. Wilson touches upon other novel agents for PrEP, as well as DoxyPEP for the prevention of bacterial STIs.

IDMythbusters: Evaluating Historical and Current Practice Patterns

By Parker Kaleo, PharmD

April 24th, 2026

Parker Kaleo, PharmD, Pgy2 ID Pharmacy Resident, presents a review of several recent controversies in infectious diseases. He addresses the optimal therapy for refractory MSSA bacteremia, the use of “cidal” versus “bacteriostatic” antimicrobials for severe infections, oral cephalosporins as step down therapy for severe infections, the penetration of cefazolin for CNS infections, and the use of isuvaconazole for Candida albicans infections. The presentation is given in a “confirmed,” “plausible,” or “busted ” format.

Diabetic Foot Infections Management for 2026

By Richard L. Oehler, MD

April 17th, 2026

Dr. Richard L. Oehler, MD, Professor of Medicine at the USF Morsani College of Medicine, presents this update on Diabetic Foot Infections (DFIs) in 2026. Focusing on recent guidelines and scientific literature, Dr. Oeher discusses DFI epidemiology, pathophysiology, and Diabetic foot exam basics. He then goes on to review diabetic vascular disease and its role in the progression of diabetic foot complications. Dr. Oehler then reviews the workup of diabetic foot infections including imaging and physical examination findings. Lastly, the management of diabetic foot osteomyelitis is discussed including treatment strategies and prevention.

Travel Medicine, Puerto Rico Edition

By Francisco Cordero-Baez, MD

April 6th, 2026

Dr. Cordero-Baez, MD, Infectious Diseases Fellow at the Morsani USF College of Medicine, presents a lighthearted (and Bad Bunny-inspired) look at travel medicine recommendations for Puerto Rico, a popular travel destination (and his home country) in the Caribbean. Dr. Cordero starts by taking a close look at Dengue, for which cases experienced a surge on the island as recently as in 2024. He then discusses Zika virus, including the viruses epidemiology, transmission vectors, clinical manifestations, and complications. Chikungunya virus is also briefly discussed. He closes by discussing ciguatera poisoning and several other transmissible syndromes.

Mechanisms of Gram Negative Resistance: Part II–Therapeutics

By Melissa O’Neal, Pharm.D

March 24th, 2026

Dr. Mel O’Neal, Infectious Diseases pharmacist at Tampa General Hospital, presents part 2 of her series on Gram Negative Resistance, focusing on therapeutics for treatment of these resistant pathogens. Dr. O’Neal begins by identifying the main resistance mechanisms, including membrane porins, efflux pumps, drug binding site mutations, and degrading enzymes (e.g., beta-lactamases.) She then systematically covers the major agents used for treating resistant gram negative rods, including the newer beta-lactamase inhibitors, cefiderocol, and third-generation tetracyclines. Cases are also presented to emphasize the topics covered.